AMARIN CORPORATION PLC

Latest Research Evaluating VASCEPA®/VAZKEPA® (icosapent ethyl) and Subgroups from the REDUCE-IT Landmark Outcomes Trial to be Presented at the American Heart Association (AHA) Scientific Sessions 2023

26 أكتوبر 2023 07:00:00 بحسب Nasdaq GlobeNewswire

 Amarin to Report Third Quarter 2023 Financial Results and Host Conference Call on November 1, 2023

19 أكتوبر 2023 07:00:00 بحسب Nasdaq GlobeNewswire

Amarin to Present at the 2023 Cantor Global Healthcare Conference

12 سبتمبر 2023 07:00:00 بحسب Nasdaq GlobeNewswire

Amarin Provides Pricing & Reimbursement Updates for VAZKEPA (icosapent ethyl) in The Netherlands and Italy

09 أغسطس 2023 15:05:01 بحسب Nasdaq GlobeNewswire

Amarin And Neopharm Announce Exclusive Commercialization Agreement for VAZKEPA® (Icosapent Ethyl) in Israel

08 أغسطس 2023 06:00:01 بحسب Nasdaq GlobeNewswire

Scottish Medicines Consortium Accepts VAZKEPA® (icosapent ethyl) to Help Reduce Cardiovascular Risk for Patients in Scotland(1)

07 أغسطس 2023 06:00:40 بحسب Nasdaq GlobeNewswire

Amarin Reports Second Quarter 2023 Financial Results

02 أغسطس 2023 06:11:03 بحسب Nasdaq GlobeNewswire

Amarin and Lotus Pharmaceuticals Announce Exclusive Partnership Agreement to Commercialize Vazkepa® (Icosapent Ethyl) in Southeast Asia and South Korea

31 يوليو 2023 07:00:01 بحسب Nasdaq GlobeNewswire

Latest Research Evaluating Clinical Benefits of VASCEPA®/VAZKEPA® (icosapent ethyl) to be Presented at the European Society of Cardiology (ESC) Congress

26 يوليو 2023 07:00:01 بحسب Nasdaq GlobeNewswire

Amarin Receives Positive Recommendation from Spanish Drug Pricing Committee for National Reimbursement of VAZKEPA® (icosapent ethyl) in Spain

25 يوليو 2023 15:05:00 بحسب Nasdaq GlobeNewswire

Amarin Board of Directors Announces Executive Compensation Program for New President and CEO Patrick Holt

20 يوليو 2023 07:00:00 بحسب Nasdaq GlobeNewswire

Amarin Appoints Patrick Holt as President and Chief Executive Officer

18 يوليو 2023 15:16:00 بحسب Nasdaq GlobeNewswire

Amarin Implements Organizational Restructuring to Strengthen the Company While Driving Patient Access to VASCEPA®/VAZKEPA® Globally

18 يوليو 2023 15:15:00 بحسب Nasdaq GlobeNewswire

Amarin Announces Vascepa® (Icosapent Ethyl) Approved to Reduce Cardiovascular Risk in the Kingdom of Saudi Arabia (KSA)

21 يونيو 2023 08:00:54 بحسب Nasdaq GlobeNewswire

Amarin to Present at Two Upcoming Investor Conferences

01 يونيو 2023 15:30:00 بحسب Nasdaq GlobeNewswire

Amarin Partner EddingPharm Receives Regulatory Approval for Vascepa® (Icosapent Ethyl) in Mainland China

01 يونيو 2023 05:00:00 بحسب Nasdaq GlobeNewswire

Amarin Highlights New Data Providing Potential Mechanistic Insight into Vascepa®/Vazkepa® (Icosapent Ethyl) Reduction of Cardiovascular Events

12 مايو 2023 10:00:00 بحسب Nasdaq GlobeNewswire

Amarin Reports First Quarter 2023 Financial Results and Provides Business Update

03 مايو 2023 06:00:01 بحسب Nasdaq GlobeNewswire

Amarin to Report First Quarter 2023 Financial Results and Host Conference Call on May 3, 2023

19 أبريل 2023 07:00:01 بحسب Nasdaq GlobeNewswire

Amarin Names Aaron Berg Interim President & Chief Executive Officer and Adds Oliver O’Connor to Company’s Board of Directors

17 أبريل 2023 06:00:00 بحسب Nasdaq GlobeNewswire